Skip to main content
Caplight Logo









iMedrix

iMedrix

Private
Milpitas, CaliforniaHealthcare & Life Scienceshttps://imedrix.com

Last Round

Grant

Mar 28, 2022

Total Funding Raised

$200,000

Company Overview

iMedrix operates in Healthcare & Life Sciences and is based in Milpitas, California. Its latest recorded funding round was a Grant round in March 2022.

iMedrix is a medical technology company that develops mobile-connected, AI-powered cardiovascular diagnostic solutions, including its flagship FDA-cleared KardioScreen device.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Telemedicine, Health IoT, Medical AI

Business Model

B2B

Customer Profile

Hardware Sales, Subscription SaaS, Government Contracts

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

iMedrix Comparables

Compare iMedrix with similar companies based on industry and business-model similarity.

iMedrix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tricog Health
83%
QT Medical, Inc.
83%
Sunfox Technologies
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

iMedrix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 28, 2022
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

iMedrix Investors

Notable investors and investment history

iMedrix investors
InvestorRounds
Philips Foundation Impact Investments B.V.VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 25, 2025

    Monthly visitors grew 460% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

iMedrix Filings

Explore SEC and related filing metadata, where available.

iMedrix filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about iMedrix's valuation, stock price, and market status.

Is iMedrix a public or private company?

iMedrix is a private company.

What is the current stock price of iMedrix?

iMedrix is a private company, so its shares have no public market price. Caplight tracks iMedrix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is iMedrix worth (valuation)?

Valuation information for iMedrix is not publicly available.

Can I buy iMedrix stock?

iMedrix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was iMedrix's last funding round?

iMedrix's most recent funding round was Grant on March 28, 2022.

Who are the main investors in iMedrix?

Key investors in iMedrix include Philips Foundation Impact Investments B.V..

Will iMedrix IPO soon?

No public IPO plans have been announced for iMedrix.

How can I track iMedrix secondary market activity?

Caplight tracks bids, offers, and trades in iMedrix's shares on secondary markets.

Firmographic Details

HeadquartersMilpitas, California
Employee Range12
Year Founded2017
Last FundingMar 28, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?